Quorum Innovations (“QI”) is building a biotherapeutics company driving one of the next important eras in medicine by engaging the body’s immune system to treat a broad range of barrier deficiencies. Founded on the vision that extracts from the human microbiome can yield microbiome biotherapeutic candidates.
Biofilms are ubiquitous in nature: they are living, microbial ecosystems, attaching to essentially any animate or inanimate surface.
Importantly, the unique nature of QI’s small molecular biotherapeutics includes beneficial immunomodulation and promotion of molecular human innate immune defense with intrinsic anti-inflammatory effects. Through QI’s innovative discovery platform founded on microbial biofilm selectivity, we have designed therapeutics safety considerations into the initial compound development phase. This takes into initial critical consideration active compound synergy with the human microbiomial-metabolic axis, and how it subsequently helps restore human microbiomial/biofilm/inflammatory homeostasis.
As a result of QI’s innovative discovery and development process, our bioprospected active compounds have safety margins often typically exceeding those in a traditional synthetic compound library. Ultimately, this will enable our therapeutics to be used across broad indications, populations (pediatric to geriatric) and tissues. Further increasing therapeutic index, QI compounds are designed for local administration to the biofilm-affected body site. Such anatomically targeted delivery minimizes toxicity, maximizes manufacturing cost efficiencies while minimizing patient risks such as resistant pathogen development sometimes associated with standard anti-microbial (particularly the planktonic model) treatment itself as well as side effects related to drug systemic exposure.
Finally, despite the fact that pathogenic biofilms cause nearly as many deaths annually as cancer, and that global unmet medical needs from resistant pathogens are at a critical all-time high, today’s medical armamentarium remains unprepared to treat any human biofilm-related infection or disease. There are currently no FDA-approved antibiotics for the treatment of medical biofilms. For these and other reasons, Quorum Innovations’ broad-spectrum, anti-biofilm, anti-inflammatory therapeutics would be unique, powerful and valuable additions to any pharmaceutical or health therapeutic investment or collaborator portfolio.